Diabetes Care, Vol 23, Issue 4 504-509, Copyright © 2000 by American Diabetes Association

ARTICLES

The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study

MB Grant, RN Mames, C Fitzgerald, KM Hazariwala, R Cooper-DeHoff, S Caballero and KS Estes
Division of Endocrinology, University of Florida, Gainesville 32610, USA. grantma@medicine.ufl.edu

OBJECTIVE: The pilot study examined the ability of octreotide to retard progression of diabetic retinopathy (DR) and delay the need for panretinal photocoagulation (PRP) in patients with advanced stages of retinal disease. RESEARCH DESIGN AND METHODS: Patients with severe nonproliferative DR (NPDR) or early non-high-risk proliferative DR (PDR) were randomly assigned to conventional diabetes management (control group, 12 patients) or to treatment with maximally tolerated doses of octreotide (200-5,000 microg/day subcutaneously; 11 patients). Ocular changes in each eye were assessed at a minimum of every 3 months for 15 months or until disease progressed to high-risk PDR requiring laser surgery. Endocrine assessments occurred at 3-month intervals during the study RESULTS: Only 1 of 22 eyes from patients treated with octreotide reached high-risk PDR requiring PRP, compared with control patients, in whom 9 of 24 eyes required PRP. The decreased incidence of progression requiring laser surgery was statistically significant if events were considered independently (P < 0.006). The incidence of ocular disease progression was only 27% in patients treated with octreotide compared with 42% in patients with conventional diabetes management. This treatment effect on whether the retina worsened approached statistical significance using repeated measures analysis (P = 0.0605). Endocrine management was similar between treatment groups. Thyroxine replacement therapy was administered to maintain a euthyroid state for all octreotide-treated patients and 7 of 12 control patients. CONCLUSIONS: Our results suggest that octreotide treatment in euthyroid patients may retard progression of advanced DR and may delay the time to laser surgery.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				S. S. Palii, A. Afzal, L. C. Shaw, H. Pan, S. Caballero, R. C. Miller, S. Jurczyk, J.-C. Reubi, Y. Tan, G. Hochhaus, et al. Nonpeptide Somatostatin Receptor Agonists Specifically Target Ocular Neovascularization via the Somatostatin Type 2 Receptor Invest. Ophthalmol. Vis. Sci., November 1, 2008; 49(11): 5094 - 5102. [Abstract] [Full Text] [PDF]

				Q. Mohamed, M. C. Gillies, and T. Y. Wong Management of Diabetic Retinopathy: A Systematic Review JAMA, August 22, 2007; 298(8): 902 - 916. [Abstract] [Full Text] [PDF]

				Z. T. Bloomgarden Diabetic Retinopathy and Diabetic Neuropathy Diabetes Care, March 1, 2007; 30(3): 760 - 765. [Full Text] [PDF]

				A. A. Kramerov, M. Saghizadeh, H. Pan, A. Kabosova, M. Montenarh, K. Ahmed, J. S. Penn, C. K. Chan, D. R. Hinton, M. B. Grant, et al. Expression of Protein Kinase CK2 in Astroglial Cells of Normal and Neovascularized Retina Am. J. Pathol., May 1, 2006; 168(5): 1722 - 1736. [Abstract] [Full Text] [PDF]

				G Tachas, S Lofthouse, C J Wraight, B F Baker, N B Sioufi, R A Jarres, A Berdeja, A M Rao, L M Kerr, E M d'Aniello, et al. A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice. J. Endocrinol., April 1, 2006; 189(1): 147 - 154. [Abstract] [Full Text] [PDF]

				C. Hernandez, E. Carrasco, R. Casamitjana, R. Deulofeu, J. Garcia-Arumi, and R. Simo Somatostatin Molecular Variants in the Vitreous Fluid: A comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects Diabetes Care, August 1, 2005; 28(8): 1941 - 1947. [Abstract] [Full Text] [PDF]

				D. S. Fong, L. P. Aiello, F. L. Ferris III, and R. Klein Diabetic Retinopathy Diabetes Care, October 1, 2004; 27(10): 2540 - 2553. [Full Text] [PDF]

				G. Varughese, P. Rao, D. Barton, and D. Warner Changes in diabetic retinopathy noticed after chemotherapy for duodenal carcinoma The British Journal of Diabetes & Vascular Disease, May 1, 2004; 4(3): 206 - 208. [PDF]

				A. F. Muller, J. J. Kopchick, A. Flyvbjerg, and A. J. van der Lely Growth Hormone Receptor Antagonists J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1503 - 1511. [Full Text] [PDF]

				J. Westerbacka, R. Bergholm, M. Tiikkainen, and H. Yki-Jarvinen Glargine and Regular Human Insulin Similarly Acutely Enhance Endothelium-Dependent Vasodilatation in Normal Subjects Arterioscler. Thromb. Vasc. Biol., February 1, 2004; 24(2): 320 - 324. [Abstract] [Full Text]

				R. N. Frank Diabetic Retinopathy N. Engl. J. Med., January 1, 2004; 350(1): 48 - 58. [Full Text] [PDF]

				N. Sengupta, S. Caballero, R. N. Mames, J. M. Butler, E. W. Scott, and M. B. Grant The Role of Adult Bone Marrow-Derived Stem Cells in Choroidal Neovascularization Invest. Ophthalmol. Vis. Sci., November 1, 2003; 44(11): 4908 - 4913. [Abstract] [Full Text] [PDF]

				T. A. Ciulla, A. G. Amador, and B. Zinman Diabetic Retinopathy and Diabetic Macular Edema: Pathophysiology, screening, and novel therapies Diabetes Care, September 1, 2003; 26(9): 2653 - 2664. [Abstract] [Full Text] [PDF]

				P. E. Spoerri, S. Caballero, S. H. Wilson, L. C. Shaw, and M. B. Grant Expression of IGFBP-3 by Human Retinal Endothelial Cell Cultures: IGFBP-3 Involvement in Growth Inhibition and Apoptosis Invest. Ophthalmol. Vis. Sci., January 1, 2003; 44(1): 365 - 369. [Abstract] [Full Text] [PDF]

				R. Simo, A. Lecube, L. Sararols, J. Garcia-Arumi, R. M. Segura, R. Casamitjana, and C. Hernandez Deficit of Somatostatin-Like Immunoreactivity in the Vitreous Fluid of Diabetic Patients: Possible role in the development of proliferative diabetic retinopathy Diabetes Care, December 1, 2002; 25(12): 2282 - 2286. [Abstract] [Full Text] [PDF]

				M. Henricsson, K. Berntorp, P. Fernlund, and G. Sundkvist Progression of Retinopathy in Insulin-Treated Type 2 Diabetic Patients Diabetes Care, February 1, 2002; 25(2): 381 - 385. [Abstract] [Full Text] [PDF]

				D. D. Klisovic, M. S. O'Dorisio, S. E. Katz, J. W. Sall, D. Balster, T. M. O'Dorisio, E. Craig, and M. Lubow Somatostatin Receptor Gene Expression in Human Ocular Tissues: RT-PCR and Immunohistochemical Study Invest. Ophthalmol. Vis. Sci., September 1, 2001; 42(10): 2193 - 2201. [Abstract] [Full Text] [PDF]

				K. M. Gehrs Efficacy of Octreotide in the Therapy of Severe Nonproliferative and Early Proliferative Diabetic Retinopathy: A Randomized Controlled Study: Response to Grant et al. Diabetes Care, January 1, 2001; 24(1): 182 - 182. [Full Text]

				M.B. Grant, R.N. Mames, C. Fitzgerald, K.M. Hazariwala, R. Cooper-DeHoff, S. Caballero, and K.S. Estes Efficacy of Octreotide in the Therapy of Severe Nonproliferative and Early Proliferative Diabetic Retinopathy: A Randomized Controlled Study: Response to Gehrs Diabetes Care, January 1, 2001; 24(1): 182-a - 183. [Full Text]